View in EDS

Improved VSV-Ebola-GP booster vaccination approach promotes antibody affinity maturation and durable anti-Ebola immunity in humans.

Saved in:
Bibliographic Details
Title: Improved VSV-Ebola-GP booster vaccination approach promotes antibody affinity maturation and durable anti-Ebola immunity in humans.
Authors: Khurana S; Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA. surender.khurana@fda.hhs.gov., Posadas O; Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA., Kardava L; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Coyle EM; Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA., Ravichandran S; Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA., Grubbs G; Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA., McConnell R; Critical Care Medicine, Clinical Research Center, National Institutes of Health, Bethesda, MD, USA., Rouphael N; Hope Clinic of the Emory Vaccine Center, Emory University, Atlanta, GA, USA., Poliquin G; Public Health Agency of Canada, Children's Hospital Research Institute, Winnipeg, Manitoba, Canada., Langley JM; Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Nova Scotia, Canada., Chu E; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Follmann DA; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Shang X; Department of Microbiology and Immunology, Center for Biomolecular Therapeutics, University of Maryland School of Medicine, Baltimore, MD, USA.; Institute for Bioscience and Biotechnology Research, Rockville, MD, USA., Li Y; Department of Microbiology and Immunology, Center for Biomolecular Therapeutics, University of Maryland School of Medicine, Baltimore, MD, USA.; Institute for Bioscience and Biotechnology Research, Rockville, MD, USA., Moir S; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Davey RT Jr; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Source: Nature immunology [Nat Immunol] 2026 May; Vol. 27 (5), pp. 1053-1065. Date of Electronic Publication: 2026 Mar 19.
Publication Type: Journal Article; Randomized Controlled Trial
Journal Info: Publisher: Nature America Inc Country of Publication: United States NLM ID: 100941354 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1529-2916 (Electronic) Linking ISSN: 15292908 NLM ISO Abbreviation: Nat Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41857394
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Improved VSV-Ebola-GP booster vaccination approach promotes antibody affinity maturation and durable anti-Ebola immunity in humans.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Khurana+S%22">Khurana S</searchLink>; Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA. surender.khurana@fda.hhs.gov.<br /><searchLink fieldCode="AU" term="%22Posadas+O%22">Posadas O</searchLink>; Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA.<br /><searchLink fieldCode="AU" term="%22Kardava+L%22">Kardava L</searchLink>; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Coyle+EM%22">Coyle EM</searchLink>; Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA.<br /><searchLink fieldCode="AU" term="%22Ravichandran+S%22">Ravichandran S</searchLink>; Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA.<br /><searchLink fieldCode="AU" term="%22Grubbs+G%22">Grubbs G</searchLink>; Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA.<br /><searchLink fieldCode="AU" term="%22McConnell+R%22">McConnell R</searchLink>; Critical Care Medicine, Clinical Research Center, National Institutes of Health, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Rouphael+N%22">Rouphael N</searchLink>; Hope Clinic of the Emory Vaccine Center, Emory University, Atlanta, GA, USA.<br /><searchLink fieldCode="AU" term="%22Poliquin+G%22">Poliquin G</searchLink>; Public Health Agency of Canada, Children's Hospital Research Institute, Winnipeg, Manitoba, Canada.<br /><searchLink fieldCode="AU" term="%22Langley+JM%22">Langley JM</searchLink>; Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Nova Scotia, Canada.<br /><searchLink fieldCode="AU" term="%22Chu+E%22">Chu E</searchLink>; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Follmann+DA%22">Follmann DA</searchLink>; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Shang+X%22">Shang X</searchLink>; Department of Microbiology and Immunology, Center for Biomolecular Therapeutics, University of Maryland School of Medicine, Baltimore, MD, USA.; Institute for Bioscience and Biotechnology Research, Rockville, MD, USA.<br /><searchLink fieldCode="AU" term="%22Li+Y%22">Li Y</searchLink>; Department of Microbiology and Immunology, Center for Biomolecular Therapeutics, University of Maryland School of Medicine, Baltimore, MD, USA.; Institute for Bioscience and Biotechnology Research, Rockville, MD, USA.<br /><searchLink fieldCode="AU" term="%22Moir+S%22">Moir S</searchLink>; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Davey+RT+Jr%22">Davey RT Jr</searchLink>; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100941354%22">Nature immunology</searchLink> [Nat Immunol] 2026 May; Vol. 27 (5), pp. 1053-1065. <i>Date of Electronic Publication: </i>2026 Mar 19.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+America+Inc%22">Nature America Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>100941354 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1529-2916 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215292908%22">15292908 </searchLink><i>NLM ISO Abbreviation: </i>Nat Immunol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41857394
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41590-026-02459-w
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1053
    Titles:
      – TitleFull: Improved VSV-Ebola-GP booster vaccination approach promotes antibody affinity maturation and durable anti-Ebola immunity in humans.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Khurana S
      – PersonEntity:
          Name:
            NameFull: Posadas O
      – PersonEntity:
          Name:
            NameFull: Kardava L
      – PersonEntity:
          Name:
            NameFull: Coyle EM
      – PersonEntity:
          Name:
            NameFull: Ravichandran S
      – PersonEntity:
          Name:
            NameFull: Grubbs G
      – PersonEntity:
          Name:
            NameFull: McConnell R
      – PersonEntity:
          Name:
            NameFull: Rouphael N
      – PersonEntity:
          Name:
            NameFull: Poliquin G
      – PersonEntity:
          Name:
            NameFull: Langley JM
      – PersonEntity:
          Name:
            NameFull: Chu E
      – PersonEntity:
          Name:
            NameFull: Follmann DA
      – PersonEntity:
          Name:
            NameFull: Shang X
      – PersonEntity:
          Name:
            NameFull: Li Y
      – PersonEntity:
          Name:
            NameFull: Moir S
      – PersonEntity:
          Name:
            NameFull: Davey RT Jr
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2026 May
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1529-2916
          Numbering:
            – Type: volume
              Value: 27
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Nature immunology
              Type: main
ResultId 1